A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia.
Phase of Trial: Phase III
Latest Information Update: 25 Sep 2015
At a glance
- Drugs Atorvastatin (Primary) ; Atorvastatin/losartan (Primary) ; Losartan
- Indications Essential hypertension; Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors HanAll Biopharma
- 22 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2013 to 1 Oct 2014.
- 06 Mar 2012 New trial record